Brought to you by 
SpePharm enters into royalty agreement with Paul Capital
01 Oct 2020
Executive Summary
Cancer and critical care company SpePharm Holdings BV has signed a €10mm ($14.75mm) revenue interest acquisition financing with Paul Capital Healthcare to fund SpePharm's recent purchase of European rights to Procter & Gamble's hyperthermia treatment Dantrium. Paul Capital also participated in a simultaneously announced €16mm equity financing for SpePharm, along with other investors.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Royalty Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SpePharm enters into royalty agreement with Paul Capital
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice